SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-99.1
Date Filed: 2025-08-14
Accession Number: 0001213900-25-076055
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025076055/ea025320101ex99-1_synergy.htm

Chunk 0 of 2
Word Count: 1498
Character Count: 10036

Document Content:

Exhibit 99.1

Synergy CHC Corp Reports Second Quarter 2025
Financial Results and

its Tenth Consecutive Quarter of Profitability

WESTBROOK, Maine, August 14, 2025 –
Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing
its financial results for the three months ended June 30, 2025.

“We are pleased to report another strong
quarter, marking our tenth consecutive quarter of profitability,” said Jack Ross, CEO of Synergy. “Revenue, gross profit,
net income and earnings per share all grew year-over-year, reflecting our continued focus on disciplined execution and profitable growth.”

“We also made significant progress across
our strategic priorities, including expanding the global footprint of our FOCUSfactor brand through a licensing agreement in Turkey. On
the beverage side, our new leadership team is already driving results, securing distribution partners across North America and advancing
the growth of our RTD business. In addition, we successfully completed a $20 million debt refinancing, which is a significant milestone
for the company. It extends our maturity profile, enhances financial flexibility and supports our long-term growth strategy. With this
improved capital structure and continued momentum, we’re well positioned to accelerate growth in the second half of 2025 and beyond.”

Second Quarter 2025 Financial Summary vs. Same
Year-Ago Period

●	Revenue of $8.1 million vs. $8.0 million.

●	Gross margin of 76.7% vs. 69.5%.

●	Income from operations of $1.62 million vs. $1.58
million.

●	Net income of $1.5 million vs. $655.2 thousand.

●	Earnings per share of $0.17 vs. $0.09.

●	EBITDA, a non-GAAP financial measure, was $3.80
million vs. $1.61 million.

Recent Business Highlights

●	Synergy recently announced a series of major
North American retail and distribution wins across its FOCUSfactor supplement and beverage lines, significantly expanding availability
across mass, grocery, pharmacy, convenience and wholesale channels, which should start yielding significant results in the fourth quarter

●	On June 18, 2025, Synergy announced the expansion
of its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates (UAE) for exclusive distribution
of FOCUSfactor.

●	On June 4, 2025, Synergy announced that it entered
into a $20 million term loan credit agreement, due May 2029, with ACP Agency, LLC, of which $17.5 million has been drawn.

●	During the second quarter, Synergy announced
the additions of key individuals to drive the Company’s beverage growth.

●	During the second quarter, the Company reduced
outstanding liabilities by $869 thousand.

●	Subsequent to the quarter end, Synergy reduced
outstanding notes payable by $1.8 million.

Second Quarter 2025 Financial Results

Revenue in the second quarter of 2025 was $8.1
million, up 1% compared to $8.0 million in the second quarter of 2024. The Company generated $1.4 million in license revenue during the
quarter.

Gross margin in the second quarter of 2025 was
76.7% compared to 69.5% in the second quarter of 2024. The increase was largely driven by license revenue.

Operating expenses in the second quarter of 2025
were $4.6 million, up 16% compared to $4.0 million in the second quarter of 2024. The increase was driven by incremental costs associated
with being a public company.

Income from operations for the second quarter
of 2025 was $1.62 million, up 2.5% compared to $1.58 million in the second quarter of 2024. The increase in operating income was due to
the improvement in gross margin.

Net income in the second quarter of 2025 was $1.5
million, up 125% compared to net income of $655.2 thousand in the second quarter of 2024.

Earnings per share in the second quarter was $0.17,
up 86% compared to $0.09 in the second quarter of 2024.

EBITDA (a non-GAAP financial measure) in the second
quarter of 2025 was $3.80 million, up 136% compared to $1.61 million in the second quarter of 2024.

Balance Sheet and Cash Flow

As of June 30, 2025, Synergy had approximately
$1.5 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

As of June 30, 2025, Synergy had a working capital
surplus of $12.4 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

As of June 30, 2025, Synergy had $2.4 million
in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the six
months ended June 30, 2025 was $899.7 thousand compared to cash used in operating activities of $1.1 million for the six months ended
June 30, 2024.

Non-GAAP Financial Measure Reconciliation:
EBITDA

To assist financial statement users in an assessment
of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and
related events, as the Company believes that the non-GAAP information enhances investors’ overall understanding of our financial performance,
and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA provides useful information
to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly
between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization.

The following table reconciles net income to EBITDA
(in millions of US dollars):

3 Months ended June 30

Net income for the period $	1.47 $	0.66

Adjusted for:

Interest expense, net 2.11 0.74

Amortization of intangible assets 0.03 0.03

Tax expense 0.19 0.18

EBITDA $	3.80 $	1.61

Conference Call

In conjunction with this announcement, Synergy
will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2025 with the Company’s Chief Executive Officer, Jack Ross,
and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations
section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To
avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the
webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health
and wellness products. Its brand portfolio includes two flagship names: FOCUSfactor, a clinically studied brain health supplement shown
to improve memory, concentration, and focus; and Flat Tummy, a lifestyle brand offering nutritional solutions designed to support women’s
wellness and weight management goals.

Forward Looking Statements

Certain statements contained in this press
release constitute “forward-looking statements,” including statements regarding expansion and growth initiatives, refinancing
of our indebtedness and our free cash flow. These forward-looking statements represent Synergy’s expectations or beliefs concerning future
events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are
subject to risks, uncertainties and other factors, which are set forth in Synergy’s registration statement on Form S-1, as amended, many
of which are outside of Synergy’s control, that could cause actual results to differ materially from the results discussed in the forward-looking
statements.

Any forward-looking statement speaks only as
of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible
for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and
other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could
cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group

Cody Slach, Greg Robles

SNYR@gateway-grp.com

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

June 30, 2025 December 31, 2024

(unaudited)

Assets

Current Assets

Cash and cash equivalents $	1,458,561 $	687,920

Restricted cash 100,000 100,000

Accounts receivable, net 7,069,889 5,321,037

Other receivables 2,025,094 1,999,637

Loan receivable (related party) 4,427,883 4,375,059

Prepaid expenses (including related party amount of $801,345 and $312,966, respectively) 2,064,094 1,859,563

Inventory, net 2,364,158 1,716,552

Total Current Assets 19,509,679 16,059,768

Intangible assets, net 216,667 283,333

Total Assets $	19,726,346 $	16,343,101

Liabilities and Stockholders’ Deficit

Current Liabilities:

Accounts payable and accrued liabilities (including payable to shareholder of $92,955 and $88,644, respectively) $	4,960,331 $	5,191,868

Income taxes payable 266,472 242,977

Contract liabilities 4,887 24,252

Short term loans payable, net of debt discount 1,894,857 7,725,272

Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder - 4,000,000

Total Current Liabilities 7,126,547 17,184,369

Long-term Liabilities:

Notes payable, net of debt discount, shareholder - 8,333,053

Notes payable, net of debt discount 24,978,999 7,457,022

Total long-term liabilities 24,978,999 15,790,075

Total Liabilities 32,105,546 32,974,444

Commitments and contingencies

Stockholders’ Deficit:

Common stock, $0.00001 par value; 300,000,000 shares authorized; 9,621,926 and 8,721,818, shares issued, respectively; 9,441,853 and 8,541,745 outstanding, respectively 96 87

Additional paid in capital 29,508,354 27,643,660